Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V503 (Gardasil 9) Immunogenicity and Lot Consistency in Adolescents vs Young Women
NCT00943722Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2009
- Primary completion
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), vulvar cancer and 2 more (5 arms), sponsored by Merck & Co. Primary endpoints: Geometric Mean Titers for Each of the HPV Types Contained in the Vaccine at Month 7, Percentage of Participants With Injection Site Adverse Experiences and 2 more. Started Aug 2009; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vulvar cancervaginal cancergenital warts
Beyond the preview
Go deeper on NCT00943722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943722.